Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Cost-Cutting Will Spare Effexor, Manufacturing Investments

Executive Summary

Wyeth will invest $60 mil. in Effexor manufacturing capacity expansion in 2003, CFO Kenneth Martin told the Credit Suisse First Boston investor conference Nov. 14 in Phoenix

You may also be interested in...



Merck Sees Chance To “Repatriate” Cash To U.S.; GSK Wants To Ship Out

Merck sees an opportunity to bring back cash to the U.S. should a tax change allowing companies to "repatriate" holdings at foreign subsidiaries be enacted by Congress this year

Merck Sees Chance To “Repatriate” Cash To U.S.; GSK Wants To Ship Out

Merck sees an opportunity to bring back cash to the U.S. should a tax change allowing companies to "repatriate" holdings at foreign subsidiaries be enacted by Congress this year

Wyeth Closes ReFacto And Premarin Facilities, Cites Low Demand As Reason

Wyeth is closing its ReFacto manufacturing plant in St. Louis due to lower demand for the antihemophilic Factor VIII product

Related Content

UsernamePublicRestriction

Register

PS040853

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel